Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301
A. A. Miller(Leukemia Research Foundation), Mark J. Ratain(University of Chicago), Miguel A. Villalona‐Calero(University of California, Irvine), Kouros Owzar(Duke University), Amisha Desai, Donna Hollis(University of North Carolina at Chapel Hill), Jinseub Hwang, Lionel D. Lewis(Dartmouth College), E. Claire Dees(University of North Carolina at Chapel Hill), G.K. Abou-Alfa(Leukemia Research Foundation), D. J. Murry(Leukemia Research Foundation)
Cited by 16
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k